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BACKGROUND 
 The management of post-operative pain holds many challenges.  The use of narcotics, 
including PCA (patient controlled analgesia), and femoral nerve blocks can limit ambulation, 
increase the length of hospital stays, and cause adverse events that hinder overall recovery.  
Liposomal bupivacaine is a non-opioid anesthetic indicated for the management of post-operative 
pain.  Studies have shown that the use of liposomal bupivacaine has been associated with a 
decrease in opiate use after total knee arthroplasty, and can offer multimodal pain management 
through the maximization of pain control while decreasing side effects.   The purpose of this study 
is to determine the effectiveness of using liposomal bupivacaine for patients undergoing partial or 
total knee arthroplasty in comparison to femoral nerve block with or without post-operative PCA.  
 The development of a liposomal formulation of local anesthetics stems from the desire to alter 
the pharmacokinetics of conventional local anesthetics, specifically to alter the short duration of 
action.  Local anesthetics typically have a short duration of action (< 7 hours), at which point 
opiates are typically used to control pain3.  The liposomal formulation of bupivacaine has a 
duration of action that is significantly longer (~96 hours), and undergoes both short-term, first-
order absorption and longer-term zero-order absorption3,4.  This leads to a two peak phenomenon 
when looking at plasma concentration over time2.  The clinical implications of this longer duration 
and two peak phenomenon are a more sustained and progressive disruption of sensory neural 
transmission. 
 Two articles from the Journal of Arthroplasty, as well as a review article evaluating liposomal 
bupivacaine for knee replacement surgery, have described the effects of using liposomal 
bupivacaine on length of stay, patient reported pain scores, and average opioid usage1,2,5.  These 
articles evaluate the effectiveness of liposomal bupivacaine compared to conventional therapy, 
and while the articles by Surdam et al. and Harrison note a trend in improved pain scores and 
decreased narcotic use, the article by Bagsby suggests that liposomal bupivacaine is not superior 
to conventional therapy.  This shows the continued need for research into the overall 
effectiveness of liposomal bupivacaine on post-procedural pain, and how it compares to 
conventional therapy. 
OBJECTIVE 
The primary outcome of this study is to determine the effect liposomal bupivacaine in addition 
to conventional therapy compared to conventional therapy alone on post-operative pain control 
after partial or total knee replacement.  Secondary outcomes evaluated included length of stay, 
time to ambulation, and patient reported pain scores on post-op day 1 and day 2, in the two 
patient populations. 
 
• This is a single-center, retrospective, cohort study was conducted in a 353 bed academic 
medical center 
• Medical records were used to identify patients over the age of 18 who have undergone knee 
replacement and received peri-operative liposomal bupivacaine in addition to conventional 
therapy or conventional therapy alone 
• Data on 150 patients was collected, with 100 patients receiving liposomal bupivacaine and 50 
control patients 
• Data on age, gender, type of surgery performed, pain scores, opiate and non-opiate pain 
medications used in the post-anesthesia care unit (PACU) and post-PACU, time to ambulation 
(50 feet), and length of stay was collected and analyzed 
• The primary outcome of pain control was measured through morphine equivalents required 
post-operatively 
 
• A total of 150 patients who had knee arthroplasty surgery were retrospectively 
evaluated, with 100 patients receiving liposomal bupivacaine injections 
• Compared to the control sample, a reduction in opiate requirements, as determined 
by morphine equivalents, was seen with liposomal bupivacaine post-PACU, but not 
in the PACU (p = 0.0003 and p = 0.085, respectively) 
• When examining secondary outcomes, a statistically significant decrease in length 
of stay and time to ambulation was seen in the liposomal bupivacaine group (length 
of stay: 1.9 days vs 2.98 days, p < 0.0001; time to ambulation: 0.38 days vs 1.76 days, 
p < 0.0001). However, liposomal bupivacaine showed no statistical difference in pain 
scores, either at 24 or 48 hours (p = 0.18 and 0.078, respectively) 
• A subgroup analysis that removed patients with extended lengths of stay (two from 
control and one from liposomal bupivacaine) revealed similar results.  Length of stay 
and daily opiate requirements remained statistically different (p <0.0002 and p = 
0.0008, respectively).  Opiate requirements in the PACU remained similar (p = 0.16) 
• Several clinical trials have been conducted with liposomal bupivacaine in knee 
replacement surgery 
• A study in press by Surdam et al.1 shows that liposomal bupivacaine decreases 
the opiate requirements POD1, while other reports vary regarding opiate use.  A 
review article by Harrison2 reports that extended release bupivacaine 
significantly decreases narcotics used, while Bagsby et al.5 reports no difference 
in opiate usage.   
• The study by Bagsby et al. also shows that liposomal bupivacaine does not 
decrease reported pain scores when compared to conventional therapy. 
• The preliminary findings of a large clinical trial by Barrington and Emerson6 





Figure 2: Mean Length of stay (in days) 
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Figure 1: Opioid requirements (in morphine equivalents) 
Figure 3: Patient reported pain scores 
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Table 1: Demographics and data analysis 
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Our data support several clinical trials, suggesting that a protocol outlining the use 
of liposomal bupivacaine in knee replacement surgery may lead to better patient 
outcomes and satisfaction.  These data have been used as the basis for updating 
current practice at Gwinnett Medical Center, leading to the addition of liposomal 
bupivacaine to the formulary for use in knee replacement surgery. 
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 Control Liposomal 
Bupivacaine 
P 
N 50 100  
Male 15 38 0.91 
Female 24 58  
Age (mean) 68 66 0.26 
Total Knee Replacement 35 82 0.096 
Partial Knee Replacements 15 18  
Length of Stay (mean) 2.98 1.9 <0.0001 
Time to Ambulation (mean) 1.76 0.38 <0.0001 
Time to D/C from PT (mean) 3.10 1.78 <0.0001 
Pain Score at 24 hours 
(mean) 
4.69 4.11 0.18 
Pain Score at 48 hours 
(mean) 
4.46 3.71 0.078 
PACU Morphine Equivalents 
(mean) 
7.00 4.89 0.085 
Non-PACU Morphine 
Equivalents (mean) 
51.33 28.73 0.0003 
Daily Morphine Equivalents 
(mean) 
21.11 12.65 0.0016 
PCA Use 43 8 <0.0001 
 
